Affomix and City of Hope Partner on Ab Selection for Next-Gen Sequencing | GenomeWeb

NEW YORK (GenomeWeb News) – Affomix said today that it will collaborate with City of Hope to establish the clinical utility of "digital proteomics" using next-generation sequencers.

As part of the collaboration, Affomix will use its high-throughput, automated antibody-selection technology to provide City of Hope with recombinant antibodies that are designed to be readily tagged with oligonucleotide "zipcodes," making them compatible with next-generation sequencers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.